期刊文献+

HSP90抑制剂对食管鳞癌细胞株TE-1凋亡的影响及作用机制 被引量:2

Effect of HSP90 inhibitor on apoptosis in esophageal squamous carcinoma cell TE-1 and its mechanism
下载PDF
导出
摘要 目的探讨抑制热休克蛋白90(Hsp90)对食管鳞癌细胞株TE-1凋亡的影响。方法采用不同浓度(0.25、0.5、1.0、2.0μmol/L)、不同时间(24、48、72 h)HSP90抑制剂17-烯丙胺-17-脱甲氧格尔德霉素(17-AAG)处理食管鳞癌细胞株TE-1,分别采用MTT法、流式细胞仪及western blot检测细胞增殖、细胞凋亡及Hsp90、Hsp70、Akt、Fas蛋白表达。结果 17-AAG对TE-1细胞体外增殖抑制率和细胞凋亡率有明显促进作用,并呈现时间-剂量依赖性。17-AAG处理后TE-1细胞Hsp90、Akt蛋白表达明显降低,Hsp70、Fas蛋白表达明显上调。结论 17-AAG可显著抑制TE-1增殖,促进凋亡,其机制可能是通过抑制Hsp90活性、影响其相关信号通路所致。 Objective To evaluate the effect of inhibition Heat shock protein 90(HSP90) on apoptosis in esophageal squamous carcinoma cell TE-1.Methods TE-1 were treated with different time(24 h,48 h or 72 h)and different concentrations(0.25 μmol/L,0.5 μmol/L,1.0 μmol/L or 2.0 μmol/L)of 17-allylamio-17-desmethoxygeldanamycin(17-AAG).The cell proliferation,apoptosis and protein expression of Hsp90,Hsp70,Akt and Fas were determined by MTT method,flow cytometry and western blot.Results The 17-AAG on TE-1 cell in vitro proliferation inhibition and apoptosis rate had obvious promoting effect,and time-dose dependent.After curcumin treatment,the protein expression of Hsp90 and Akt significantly reduced,Hsp70 and Fas significantly increased.Conclusion 17-AAG can significantly inhibit the proliferation of TE-1,promote apoptosis,its mechanism may be through inhibiting Hsp90 activity and influence the related signaling pathway.
出处 《分子影像学杂志》 2015年第3期186-189,共4页 Journal of Molecular Imaging
基金 广东省科技厅2013年自筹经费类科技计划项目
关键词 HSP90 食管鳞癌 17-AAG 增殖 凋亡 HSP90 Esophageal squamous carcinoma 17-AAG Proliferation Apoptosis
  • 相关文献

参考文献12

  • 1李红梅,聂丽娟,霍强,赵素容,马涛,吴成柱,刘浩.Hsp90抑制剂槚如酸对乳腺癌MDA-MB-231细胞增殖、侵袭、迁移的影响[J].南方医科大学学报,2015,35(3):355-359. 被引量:9
  • 2赵志敏,柳晓春,王秀娥,戚欣,李静.Hsp90分子抑制剂拮抗肿瘤耐药的研究进展[J].现代生物医学进展,2014,14(15):2967-2971. 被引量:4
  • 3陈美霓,许静洪,赵菊梅.HSP90抑制剂17-AAG对胃癌SGC-7901细胞生长周期和凋亡的影响[J].南方医科大学学报,2013,33(2):271-275. 被引量:6
  • 4刘毅,王颖,刘晓丹,杨平地,于晓妉.热休克蛋白90抑制剂17-AAG诱导K562细胞凋亡作用的研究[J].中华血液学杂志,2006,27(12):809-812. 被引量:7
  • 5Youhei Tanaka,Hidenobu Kamohara,Kouichi Kinoshita,Junji Kurashige,Takatsugu Ishimoto,Masaaki Iwatsuki,Masayuki Watanabe,Hideo Baba.Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma[J]. Cancer . 2012 (6)
  • 6Xiangyi Lu,Li Xiao,Luan Wang,Douglas M. Ruden.Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs[J]. Biochemical Pharmacology . 2011 (8)
  • 7Katherine J.O’Malley,GabrielleLangmann,JunkuiAi,RaquelRamos‐Garcia,Robert L.Vessella,ZhouWang.Hsp90 inhibitor 17‐AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance[J]. Prostate . 2012 (10)
  • 8Sang J,Acquaviva J,Friedland JC,et al.Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov . 2013
  • 9Wu Chen,Kraft Peter,Zhai Kan,Chang Jiang,Wang Zhaoming,Li Yun,Hu Zhibin,He Zhonghu,Jia Weihua,Abnet Christian C,Liang Liming,Hu Nan,Miao Xiaoping,Zhou Yifeng,Liu Zhihua,Zhan Qimin,Liu Yu,Qiao Yan,Zhou Yuling,Jin Guangfu,Guo Chuanhai,L.Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nature Genetics . 2012
  • 10Gomez F,Chen L,Wierda W,et al.In vitro effect of AZD1208 (Pim Kinase Inhibitor)and 17-AAG (HSP90 Inhibitor)combination in CLL. Cancer Research . 2013

二级参考文献82

  • 1Li, Qian,Peng, Jie,Li, Xin-Hua,Liu, Ting,Liang, Qing-Chun,Zhang, Gui-Ying.Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues[J].World Journal of Gastroenterology,2010,16(10):1274-1278. 被引量:11
  • 2Neckers L.Hsp90 inhibitors as novel cancer chemothcrapcutics agents.Trends mol Med,2002,8:S55-61.
  • 3Shiotsu Y,Neckers LM,Wortman I,et al.Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.Blood,2000,96:2284-2291.
  • 4An WG,Schulte TW,Neckers LM.The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and vsrc proteins before their degradation by the proteasome.Cell Growth Differ,2000,7:355-360.
  • 5Gorre ME,Yen KE,Chiosis G,et al.BCR-ABL point mutants isolated from patients with imatinib mesylate-resisitant chronic mycloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.Blood,2002,100:3041-3044.
  • 6Hawkins LM,Jayanthan AA,Narendran A.Effects of 17-allylamino-17-demethoxygeldanamycin(17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mcsylate sensitivity.Pediatr Res,2005,57:430-437.
  • 7Radujkovic A,Schad M,Topaly J,et al.Synergistic activity of imatinib and 17-AAG in imatinib-resisitant CML cells overexpressing BCR-ABL inhibition of P-glycoprotein function by 17-AAG.Leukemia,2005,19:1198-1206.
  • 8Holcik M,Gibson H,Korneluk RG.XIAP:Apoptotic brake and promising therapeutic target.Apoptosis,2001,6:253-261.
  • 9Zaffaroni N,Pennati M,Daidone MC.Survivin as a target for new anticancer interventions.J Cell Mol Med,2005,9:360-372.
  • 10Guo F,Racha K,Bali P,et al.Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.Cancer Res,2005,65:10536-10544.

共引文献24

同被引文献25

  • 1Solomon DA,Kim JS,Cronin JC, et al. Mutational in- activation of PTPRD in glioblastoma multiforme and malignant melanoma [J]. Cancer Res, 2008,68 (24) :10300-10306.
  • 2Cox,C,Bignell G,Greenman C,et al. A survey of ho- mozygous deletions in human cancer genomes [J]. Proc Natl Acad Sci USA, 2005,102 (12) : 4542-4547.
  • 3Sato M, Takahashi K, Nagayama K, et al. Identifica- tion of chromosome arm 9p as the most frequent tar- get of homozygous deletions in lung cancer[J]. Genes Chromosomes Cancer,2005,44(4) :405-414.
  • 4Stallings RL, Nair P, Marls JM, et al. High-resolution analysis of chromosomal breakpoints and genomic in- stability identifies PTPRD as a candidate tumor sup- pressor gene in neuroblastoma[J]. Cancer Res, 2006, 66(7) : 3673-3680.
  • 5Stark M, Hayward N. Genome-wide loss of heterozy- gosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays [J]. Cancer Res,2007,67(6) :2632-2642.
  • 6Purdie K J, Lambert SR, Teh MT, et al. Allelic imbal- ances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis [J]. Genes Chromosomes Cancer, 2007,46 (7) : 661- 669.
  • 7Nagayama K, Kohno T, Sato M, et al. Homozygous deletion scanning of the lung cancer genome at a 100- kb resolution[J]. Genes Chromosomes Cancer, 2007, 46(11) :1000-1010.
  • 8Weir BA, Woo MS,Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma[J]. Nature, 2007,450(7171) :893-898.
  • 9Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal canc- ers[J]. Science,2006,314(5797) :268-274.
  • 10Veeriah S, Brennan G, Meng S, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers[J]. Proc Natt Acad Sci U S A,2009,106(23) :9435-9440.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部